Shamburg News · 8-K filed Nov 16, 2026, 8:35 AM EST

Aptevo Reports Third Quarter 2026 Results and Mipletamig Clinical Update

APVO · Aptevo Therapeutics Inc.

  • Earnings
  • Financing
  • Materiality: high

Aptevo Therapeutics reported financial results for the quarter ended September 30, 2026, with a net loss of $6.5 million compared with $7.5 million for the third quarter of 2025. Cash and cash equivalents totaled $8.3 million as of September 30, 2026, down from $9.8 million as of June 30, 2026. The company also disclosed an August 2026 warrant inducement and private placement that generated gross proceeds of approximately $4.5 million.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193125-26-462254.

Written from the filing by Shamburg Markets. Figures are as reported by the company.